Coronary Artery Disease (CAD) (Ischemic Heart Disease) – Drugs In Development, 2024
Powered by ![]()
Unlock hidden opportunities in the Pharmaceuticals industry
Empower your strategies with our Coronary Artery Disease (CAD) (Ischemic Heart Disease) – Drugs In Development, 2024 report and make more profitable business decisions.
Coronary artery disease (CAD) is the most common type of heart disease. CAD happens when the arteries that supply blood to heart muscle become hardened and narrowed. This is due to the buildup of cholesterol and other material, called plaque, on their inner walls. This buildup is called atherosclerosis. As it grows, less blood can flow through the arteries. As a result, the heart muscle can’t get the blood or oxygen it needs. This can lead to chest pain (angina) or a heart attack. Most heart attacks happen when a blood clot suddenly cuts off the heart’s blood supply, causing permanent heart damage. The most common symptom of coronary artery disease is angina, or chest pain. Other symptoms include shortness of breath, palpitations, a faster heartbeat, weakness or dizziness, nausea, and sweating.
The Coronary Artery Disease (CAD) (Ischemic Heart Disease) drugs in development market research report provide comprehensive information on the therapeutics under development for Coronary Artery Disease (CAD) (Ischemic Heart Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action and product description of the therapeutics, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Coronary Artery Disease (CAD) (Ischemic Heart Disease) and features dormant and discontinued products.
Note:
* This is an “on-demand” report and will be delivered within 2 business days (excluding weekends and holidays) of the purchase.
* Certain sections in the report may be removed or altered based on the availability and relevance of data.
| Quick View – Coronary Artery Disease (CAD) (Ischemic Heart Disease) | Key Targets |
|
|
| Key Mechanisms of Action |
|
||
| Key Routes of Administration |
|
||
| Key Molecule Types |
|
||
| Major Companies |
|
||
Scope
- Therapeutics in Development: Covering 66 molecules, with 62 developed by companies and the rest by universities/institutes.
- Analysis Parameters: Offering insights by stage of development, drug target, MoA, RoA, and molecule type for a comprehensive overview.
- Pharmacological Insights: Understand the descriptive pharmacological action of therapeutics.
- Development History: Access the complete research and development history.
- Latest News and Press Releases: Stay updated with the latest developments through comprehensive news coverage.
Reasons to Buy
- Holistic insights: Understand the broad spectrum of Coronary Artery Disease (CAD) (Ischemic Heart Disease) therapeutics, aiding strategic decision-making with insights into stages, targets, MoA, RoA and molecule types.
- Pipeline Exploration: Explore the detailed Coronary Artery Disease (CAD) (Ischemic Heart Disease) pipeline, offering nuanced analysis of drug targets, mechanisms of action and routes of administration for varied decision-making.
- Comprehensive R&D: Access thorough R&D histories, providing a comprehensive understanding of Coronary Artery Disease (CAD) (Ischemic Heart Disease) treatments for adaptable decision-making.
- Save valuable hours: Identify key players steering innovation in therapeutics, enabling strategic partnerships.
Key Players
3BIGS Co LtdadvanceCor GmbH
AgeX Therapeutics Inc
Ascendia Pharmaceuticals Inc
AstraZeneca Plc
Athera Biotechnologies AB
Bayer AG
Beijing SH biotechnology Co Ltd
Bilix Co Ltd
Bio-Thera Solutions Ltd
Brillian Pharma Inc.
Bristol-Myers Squibb Co
Capricor Therapeutics Inc
CeleCor Therapeutics Inc
Cell2Cure Aps
Cellix Bio Pvt Ltd
Chengdu Shibeikang Biomedical Technology Co Ltd
CSL Ltd
Cynata Therapeutics Ltd
DalCor Pharmaceuticals Inc
Dalian Wista Pharmaceutical Co Ltd
Diapin Therapeutics LLC
Eight Plus One Pharmaceutical Co Ltd
F. Hoffmann-La Roche Ltd
G&P Bioscience Co Ltd
Guangzhou Yipinhong Pharmaceutical Co Ltd
Han Wha Pharma Co Ltd
Helixmith Co Ltd
Hemostemix Inc
Heqet Therapeutics Srl
Honya Medical Inc
Hyloris Pharmaceuticals SA
Imbria Pharmaceuticals Inc
Innolife Co Ltd
Jaan Biotherapeutics LLC
LipimetiX Development Inc
MabTics
Mandos LLC
MD Healthcare Inc
Novartis AG
Orion Corp
Pharmahungary Group
Regio Biosciences
Resverlogix Corp
Shanghai Pharmaceutical Group Co Ltd
Starpax Biopharma Inc
Tianjin Institute of Pharmaceutical Research
University of Debrecen
University of Oxford
Venturis Therapeutics Inc
Verseon Corp
VESSL Therapeutics Ltd
Virtual Drug Development Inc
XyloCor Therapeutics Inc
Yale University
Zhittya Genesis Medicine Inc
Table of Contents
Table
Figures
Frequently asked questions